{"id":4775,"date":"2011-01-19T00:00:00","date_gmt":"2011-01-19T00:00:00","guid":{"rendered":"http:\/\/www.pharma-mkting.com\/index.php\/2011\/01\/19\/pmnissuev102jan2011archive\/"},"modified":"2019-02-18T19:34:57","modified_gmt":"2019-02-18T19:34:57","slug":"pmnissuev102jan2011archive","status":"publish","type":"post","link":"http:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/articles\/pmnissuev102jan2011archive\/","title":{"rendered":"Pharma Marketing News Vol. 10, No. 2: JANUARY 19, 2011"},"content":{"rendered":"

Vol. 10, Issue No. 2: 19 JANUARY 2011 – EXECUTIVE SUMMARY<\/b>Deal with Lack of Regulations by Developing Best Practices Pharma’s interest in social media is a global phenomenon. <\/p>\n

\"ConfusedI’ve traveled to the UK and Germany in the past year to present at conferences about what’s happening on the pharmaceutical social media front here in the U.S. and its impact on pharmaceutical marketing elsewhere in the world.<\/p>\n

My next trip to Europe will be to Milano<\/b>, Italy, where I will speak at the 6th Annual Pharma Marketing & Branding Excellence<\/b> conference on January 25.<\/p>\n

The title of my presentation is “A Social Media Strategy: Deal with Regulations, Develop Best Practices.” When I came up with that title, I was pretty sure the FDA would have issued some guidance on social media regulations before I would make my presentation. Now, however, it appears that there will be nothing that pharma needs to deal with in terms of complying with FDA’s written regulatory guidance because there is none. So, the industry must continue to deal with a LACK of guidance. That’s fine, because guidance or no guidance, best practices in social media communications is still evolving and there will be plenty for me to talk about.<\/p>\n

Read this entire OpEd piece here:
http:\/\/www.news.pharma-mkting.com\/PMNews_102_Upfront.pdf<\/a><\/b> Strategies for Marketing Compliance A Few Thoughts from a Physician’s Point of View<\/p>\n

According to the analysts at Gartner, it is possible that a life science company will be fined $1 billion for marketing non-compliance this year.<\/p>\n

All pharma companies face a communications crisis that rests on the changing role of the medical sales representative. This evolution has a direct impact on the obligations of the pharma marketing organizations to be both proactive and responsive in helping to protect their organizations from the threat of non-compliance.<\/p>\n

What can marketing do? This article offers a few thoughts from a physician’s point of view, written by Jonathan Sackier, M.B., Ch.B., FRCS, FACS who is a regular blogger at www.goodpromotionalpractices.com<\/a>. <\/p>\n

Topics include: <\/p>\n